{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:26Z","timestamp":1791357206090,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s10194-019-1032-x","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T10:50:42Z","timestamp":1564483842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials"],"prefix":"10.1186","volume":"20","author":[{"given":"Li Shen","family":"Loo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Schim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Baygani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6559-1014","authenticated-orcid":false,"given":"Martha","family":"Port","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"1032_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","volume":"19","author":"TJ Steiner","year":"2018","unstructured":"Steiner TJ, Stovner LJ, Vos T et al (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19:17. 2018\/02\/23. \n                              https:\/\/doi.org\/10.1186\/s10194-018-0846-2","journal-title":"J Headache Pain"},{"key":"1032_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"Collaborators GDaIIaP","year":"2017","unstructured":"Collaborators GDaIIaP (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211\u20131259. 2017\/09\/19. \n                              https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2","journal-title":"Lancet"},{"key":"1032_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343\u2013349. 2007\/01\/31. \n                              https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurology"},{"key":"1032_CR4","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F et al (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78:1337\u20131345. 2012\/04\/25. \n                              https:\/\/doi.org\/10.1212\/WNL.0b013e3182535d20","journal-title":"Neurology"},{"key":"1032_CR5","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1212\/CON.0000000000000199","volume":"21","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD (2015) Preventive Migraine Treatment. Continuum (Minneap Minn) 21:973\u2013989. 2015\/08\/08. \n                              https:\/\/doi.org\/10.1212\/CON.0000000000000199","journal-title":"Continuum (Minneap Minn)"},{"key":"1032_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers S, Afra J, Frese A et al (2009) EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 16:968\u2013981. 2009\/08\/28. \n                              https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02748.x","journal-title":"Eur J Neurol"},{"key":"1032_CR7","unstructured":"Kline GS. Imitrex: Highlights of Prescribing Information, \n                              https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020132s024s026lbl.pdf\n                              \n                            (2017, Accessed 10 Mar 2019)"},{"key":"1032_CR8","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, Phebus LA, Johnson KW et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30:1159\u20131169. 2010\/09\/22. \n                              https:\/\/doi.org\/10.1177\/0333102410370873","journal-title":"Cephalalgia"},{"key":"1032_CR9","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L et al (2018) Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology 91:e2222\u2013e2232. 2018\/11\/18. \n                              https:\/\/doi.org\/10.1212\/WNL.0000000000006641","journal-title":"Neurology"},{"issue":"7","key":"1032_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"Peter J Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha L, Dennehy EB et al (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019. \n                              https:\/\/doi.org\/10.1093\/brain\/awz134\n                              \n                           . [Epub ahead of print]","journal-title":"Brain"},{"issue":"Suppl 1","key":"1032_CR11","first-page":"9","volume":"24","author":"Headache Classification Subcommittee of the International Headache S","year":"2004","unstructured":"Headache Classification Subcommittee of the International Headache S (2004) The International Classification of Headache Disorders. Cephalalgia 24(Suppl 1):9\u2013160 2004\/02\/26","journal-title":"Cephalalgia"},{"key":"1032_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.289.1.65","volume":"289","author":"E Tronvik","year":"2003","unstructured":"Tronvik E, Stovner LJ, Helde G et al (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289:65\u201369 2002\/12\/31","journal-title":"JAMA"},{"key":"1032_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/0333102413515348","volume":"\\","author":"LJ Stovner","year":"2014","unstructured":"Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 2014; \\: 523\u2013532. 2013\/12\/18. DOI: \n                              https:\/\/doi.org\/10.1177\/0333102413515348","journal-title":"Cephalalgia"},{"key":"1032_CR14","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ et al (2016) Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:1818\u20131826. 2016\/05\/11. \n                              https:\/\/doi.org\/10.1212\/WNL.0000000000002560","journal-title":"Neurology"},{"key":"1032_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793\u2013803. 2010\/07\/22. \n                              https:\/\/doi.org\/10.1177\/0333102410364676","journal-title":"Cephalalgia"},{"key":"1032_CR16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804\u2013814. 2010\/07\/22. \n                              https:\/\/doi.org\/10.1177\/0333102410364677","journal-title":"Cephalalgia"},{"key":"1032_CR17","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1526-4610.2006.00531.x","volume":"46","author":"WJ Becker","year":"2006","unstructured":"Becker WJ, Christie SN, Ledoux S et al (2006) Topiramate prophylaxis and response to triptan treatment for acute migraine. Headache 46:1424\u20131430. 2006\/10\/17. \n                              https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00531.x","journal-title":"Headache"},{"key":"1032_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1526-4610.2011.02027.x","volume":"52","author":"JL Seeburger","year":"2012","unstructured":"Seeburger JL, Cady RK, Winner P et al (2012) Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis. Headache 52:57\u201367. 2011\/11\/15. \n                              https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02027.x","journal-title":"Headache"},{"key":"1032_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000112899","volume":"38","author":"PG Cleland","year":"1997","unstructured":"Cleland PG, Barnes D, Elrington GM et al (1997) Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur Neurol 38:31\u201338. 1997\/01\/01. \n                              https:\/\/doi.org\/10.1159\/000112899","journal-title":"Eur Neurol"},{"key":"1032_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.0306-5251.2001.01417.x","volume":"52","author":"MR Goldberg","year":"2001","unstructured":"Goldberg MR, Sciberras D, De Smet M et al (2001) Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B\/1D agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol 52:69\u201376 2001\/07\/17","journal-title":"Br J Clin Pharmacol"},{"key":"1032_CR21","volume-title":"A study of lasmiditan in healthy participants when co-administered with topiramate. ClinicalTrials.gov: US government","author":"Company ELa","year":"2018","unstructured":"Company ELa. A study of lasmiditan in healthy participants when co-administered with topiramate. ClinicalTrials.gov: US government, 2018"},{"key":"1032_CR22","volume-title":"A study of lasmiditan and propranolol in healthy participants. ClinicalTrials.gov: US Government","author":"Company ELa","year":"2017","unstructured":"Company ELa. A study of lasmiditan and propranolol in healthy participants. ClinicalTrials.gov: US Government, 2017"},{"key":"1032_CR23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921\u2013936. 2010\/05\/22. \n                              https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01678.x","journal-title":"Headache"},{"key":"1032_CR24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1468-2982.2004.00754.x","volume":"24","author":"S Evers","year":"2004","unstructured":"Evers S, Vollmer-Haase J, Schwaag S et al (2004) Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Cephalalgia 24:838\u2013843. 2004\/09\/21. \n                              https:\/\/doi.org\/10.1111\/j.1468-2982.2004.00754.x","journal-title":"Cephalalgia"},{"key":"1032_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen L, Sacco S, Ashina M et al (2018) Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain 19:91. 2018\/09\/28. \n                              https:\/\/doi.org\/10.1186\/s10194-018-0921-8","journal-title":"J Headache Pain"},{"key":"1032_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1526-4610.2006.00631.x","volume":"47","author":"S Diamond","year":"2007","unstructured":"Diamond S, Bigal ME, Silberstein S et al (2007) Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 47:355\u2013363. 2007\/03\/21. \n                              https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00631.x","journal-title":"Headache"},{"key":"1032_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/qjmed\/89.8.613","volume":"89","author":"RJ Scott","year":"1996","unstructured":"Scott RJ, Aitchison WR, Barker PR et al (1996) Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice. QJM 89:613\u2013622 1996\/08\/01","journal-title":"QJM"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-019-1032-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-019-1032-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-019-1032-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T23:04:44Z","timestamp":1595459084000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-019-1032-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1186\/s10194-019-1032-x","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"2 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocols were reviewed and approved by the appropriate institutional review board for each of the study sites. The studies were conducted according to Good Clinical Practice and the Declaration of Helsinki guidelines. Patients provided written informed consent before undergoing study procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LSL is an employee of Eli Lilly and Company and\/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.JA has received personal compensation from Alder, Amgen, Allergan, Avanir, Avent, electroCore, Eli Lilly, Impel, Miller Communications, Promius, Satsuma, Teva for consulting and speaking. She has served as a section editor for Current Pain and Headache Reports. She has received research support from the American Migraine Foundation and the ARMR registry.JS received personal compensation from Acorda, Alder, Allergan, Amgen, Avanir, Depomed, electroCore, Eli Lilly, Novartis, Pernix, Promius, Supernus, Teva, and Upsher-Smith for consulting and speaking. He has received research support from Alder, Allergan, Amgen, electroCore, Eli Lilly, and Teva.SB is an employee of Eli Lilly and Company and\/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.HPH is an employee of Eli Lilly and Company and\/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.MP is an employee of Eli Lilly and Company and\/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.JHK is an employee of Eli Lilly and Company and\/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}